maps • volume xv number 3 • Winter 2005


 

As ibogaine is not regulated in Canada as it is in the US, this affords us a unique opportunity to conduct much needed research on ibogaine-assisted therapy.


 
 

Ibogaine Outcome Study:
A Progress Report on the Iboga Therapy House

Sandra Karpetas
Project Director
Iboga Therapy House

I am pleased to announce that through the generous funding, assistance and mentorship of MAPS and after many long months of setbacks and challenges, the Iboga Therapy House is now a non-profit entity ready to open the doors of our ibogaine clinic in Canada.

Our program is based on a holistic harm reduction and health promotion-based approach to recovery and personal exploration. It is our goal to facilitate an improvement in the quality of life of those seeking recovery from chemical dependence to substances such as heroin, methadone and other opiates, crack, cocaine, methamphetamine and alcohol in a safe and supportive environment to support the psychospiritual and therapeutic exploration of deeper issues through processes facilitated by the powerful experience that ibogaine may catalyze.

This project aims to complement the range of existing drug treatment options with an Ibogaine therapy service that recognizes that reductions in problematic use, changes in patterns of use toward forms of use that are less problematic, and sustained periods of prolonged abstinence all contribute to healthier lifestyles, increase resiliency and in turn contribute to improvements in quality of life for the drug addicted population.

Our staff consists of two Emergency Medical Technicians (1st Aid Level 3) to be present in case of an emergency, nine facilitators with a wide range of skills to monitor and support the participants in their treatment, two of which are professional substance abuse counselors, plus a host of community volunteers offering aftercare services such as bodywork/massage therapy, ecstatic dance, guided breathwork, reiki, light exercise such as yoga and nutritional planning. Several doctors have also requested to observe the treatments.

As ibogaine is not regulated in Canada as it is in the US, this affords us a unique opportunity to conduct much needed research on ibogaine-assisted therapy.

MAPS will provide the evaluation and research component by conducting a one-year follow-up study using information collected from 20 people treated at the Iboga Therapy House. Valerie Mojeiko of MAPS and Leah Martin of the Iboga Therapy House will coordinate the study.

The evaluation tools have been chosen to be reliable, well validated, and repeatable. Special consideration is given to measures that assess several indicators of success in addition to abstinence. The primary measure is the Addiction Severity Index, a widely used index that measures seven problem areas to obtain a comprehensive picture of a person’s life and lifestyle. Secondary measures include the Beck Depression and Anxiety Inventories, Subjective and Objective Opiate Withdrawal Scales, Peak Experience Profile (for measuring content of Ibogaine experience and how it relates to recovery), and pain and craving scales. We hope to show that ibogaine-assisted therapy is associated with extended periods of abstinence, and that intensity of the ibogaine experience will be associated with longer periods of abstinence.

A copy of the protocol design can be found on the MAPS website on the Ibogaine research page at www.maps.org/ibogaine

Over the last few months we have developed a program manual that is intended to serve as a protocol for our own upcoming program and as a potential model for ibogaine treatment and research in Canada.

It is of great interest to develop strategies for communicating with people in other fields of interest or study, to open dialogue about other psychedelics and entheogenic substances that have value as therapeutic agents of self-discovery. Increased interest and understanding of these potentials could lead to changes in the societal perception of psychedelics and lead to educated changes in drug policy, opening the door towards further research into a range of potential beneficial uses in legal contexts.

We are now accepting applications for Ibogaine-assisted therapy from chemically dependant applicants wishing to participate in our study. We plan to conduct our first treatments in November 2005 and to complete the treatment phase of this study in the spring of 2006. For more information about our program, how to apply and the costs of treatment please see our website at: www.ibogatherapyhouse.net

Many thanks to all the supporters of MAPS for your assistance in making this project a reality!

If you would like to make a donation to this project go to: www.maps.org/donate and specify “Iboga Therapy House"

Spring 2010 Vol. 20, No. 1 Special Edition: Psychedelics, Death and Dying
Autumn 2009 Vol. 19, No. 3 MAPS Financial Report: Fiscal Year 2008-09
Summer 2009 Vol. 19, No. 2 MAPS Research Update 2009
Spring 2009 Vol. 19, No. 1 Special Edition: Psychedelics and Ecology
Winter 2008/09 Vol. 18, No. 3 MAPS 2008 Financial Report
Summer 2008 Vol. 18, No. 2 Phoenix Rising: A Review of MAPS Research
Spring 2008 Vol. 18, No. 1 Special Edition: Technology and Psychedelics
Winter 2007 Vol. 17, No. 3 MAPS 06-07 Fiscal Yearly Report
Autumn 2007 Vol. 17, No. 2 Special Edition: Psychedelics and Self-Discovery
Spring/Summer 2007 Vol. 17, No. 1 The Chrysalis Stage
Winter 2006-7 Vol. 16, No. 3 Low Maintenance/High Performance
Autumn 2006 Vol. 16, No. 2 Technologies of Healing
Spring 2006 Vol. 16, No. 1 MAPS' 20th Anniversary
Winter 2005 Vol. 15, No. 3 MAPS final year as a teenager
Summer 2005 Vol. 15, No. 2 Israel Conference: MDMA/PTSD Research
Spring 2005 Vol. 15, No. 1 Accelerating flow of work and time
Autumn 2004 Vol. 14, No. 2 Rites of Passage: Kids and Psychedelics
Summer 2004 Vol. 14, No. 1 10 stamps and $250,000
Winter 2003 Vol. 13, No. 2 Holy Fire
Spring 2003 Vol. 13, No. 1 60th Anniversary of the Discovery of LSD
Autumn 2002 Vol. 12, No. 3 Vision
Summer 2002 Vol. 12, No. 2 "From celebration to frustration, and back again."
Spring 2002 Vol. 12, No. 1 Sex, Spirit & Psychedelics 2002
Autumn 2001 Vol. 11, No. 2 "In the future, it will be called Despair."
Spring 2001 Vol. 11, No. 1 "A Tidal Wave of Ecstasy!"
Autumn 2000 Vol. 10, No. 3 Creativity 2000
Summer 2000 Vol. 10, No. 2 Endings and Beginnings
Spring 2000 Vol. 10, No. 1 Making History in Slow Motion
Winter 1999/00 Vol. 9, No. 4 To the Ends of the Earth for MDMA Research...
Autumn 1999 Vol. 9, No. 3 MAPS' long-standing efforts to conduct...
Summer 1999 Vol. 9, No. 2 MAPS has come full circle...
Spring 1999 Vol. 9, No. 1 Patience, persistence and passion
Winter 1998/99 Vol. 8, No. 4 One of special pleasures of directing MAPS...
Autumn 1998 Vol. 8, No. 3 The Ayahuasca Issue (with Hofmann interview)
Summer 1998 Vol. 8, No. 2 Emotionally Powerful Anecdotes...
Spring 1998 Vol. 8, No. 1 Death Has a Way of Focusing One's Attention
Autumn 1997 Vol. 7, No. 4 Celebration is in Order
Summer 1997 Vol. 7, No. 3 Time Horizons
Spring 1997 Vol. 7, No. 2 Synchronicity
Winter 1996/97 Vol. 7, No. 1 Learning to Crawl
Autumn 1996 Vol. 6, No. 4 An Invitation for Dialogue
Summer 1996 Vol. 6, No. 3 Budding Research
New Year 1996 Vol. 6, No. 2 Sending Down Roots
Autumn 1995 Vol. 6, No. 1 Baby Steps
Summer 1995 Vol. 5, No. 4 Opportunity Amidst Obstacles
Winter 1994/95 Vol. 5, No. 3 Clinical Trials and Tribulations
Autumn 1994 Vol. 5, No. 2 Building Towards Clinical Trials
Summer 1994 Vol. 5, No. 1 Politics and Protocols: In Search of a Balance
Spring 1994 Vol. 4, No. 4 Laying the Groundwork
Winter 1993/94 Vol. 4, No. 3 A Time of Tests
Summer 1993 Vol. 4, No. 2 So Close Yet So Far
Spring 1993 Vol. 4, No. 1 Remembrance and Renewal
Winter 1992/93 Vol. 3, No. 4 Forging New Alliances
Summer 1992 Vol. 3, No. 3 Building on Common Ground
Spring 1992 Vol. 3, No. 2 Small Steps, Gradual Progress, New Opportunities
Winter 1991/92 Vol. 3, No. 1 The Rekindling of a Thousand Points of Light
Summer 1991 Vol. 2, No. 2 MDMA protocol development with cancer patients
Winter 1990/91 Vol. 2, No. 1 MAPS' Swiss pharmacologically-assisted psychotherapy conference
Autumn 1990 Vol. 1, No. 3 What and Who is MAPS?
Summer 1989 Vol. 1, No. 2 Switzerland Leads the Way
Summer 1988 Vol. 1, No. 1 MDMA can become a legal medicine